Functions and regulation of the PTEN gene in colorectal cancer

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Molinari, Francesca ^a   Frattini, Milo ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Colorectal cancer; EGFR targeted therapies; Immunohistochemistry; Mutation; Predictive; Prognosis; Pten

Indexed keywords

CETUXIMAB; IRINOTECAN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DNA METHYLATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONHUMAN; POINT MUTATION; PROTEIN DEPHOSPHORYLATION; PTEN GENE;

EID: 84893666292     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00326     Document Type: Article

References (61)

1. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 99:323-34. doi:10.1016/S0092-8674(00)81663-3
2. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 273:13375-8. doi:10.1074/jbc.273.22.13375
3. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 22:2954-63. doi:10.1200/JCO.2004.02.141
4. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res (2010) 16:4325-30. doi:10.1158/1078-0432.CCR-09-2990
5. Song MS, Salmena L, PandolfiPP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 13:283-96. doi:10.1038/nrm3330
6. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 382:1-11. doi:10.1042/BJ20040825
7. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene (2008) 27:5464-76. doi:10.1038/onc.2008.243
8. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4:127-50. doi:10.1146/annurev.pathol.4.110807.092311
9. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 157:1097-103. doi:10.1016/S0002-9440(10)64624-X
10. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 455:813-7. doi:10.1038/nature07290
11. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 95:13513-8. doi:10.1073/pnas.95.23.13513
12. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett (2006) 241:184-96. doi:10.1016/j.canlet.2005.11.042
13. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 7(8):606-19. doi:10.1038/nrg1879
14. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 16:64-7. doi:10.1038/ng0597-64
15. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet (2002) 70:829-44. doi:10.1086/340026
16. Grønbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jensen K. Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 91:4388-90.
17. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res (2001) 7:2636-42.
18. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PloS Biol (2003) 1:E59. doi:10.1371/journal.pbio.0000059
19. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol (2001) 158:1895-8. doi:10.1016/S0002-9440(10)64656-1
20. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg (2006) 243:833-42. doi:10.1097/01.sla.0000220040.66012.a9
21. Colakoglu T, Yildirim S, Kayaselcuk F, Nursal TZ, Ezer A, Noyan T, et al. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg (2008) 195:719-25. doi:10.1016/j.amjsurg.2007.05.061
22. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res (2013) 19:3285-96. doi:10.1158/1078-0432.CCR-12-3614
23. Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet (2000) 9:283-7. doi:10.1093/hmg/9.2.283
24. Shin KH, Park YJ, Park JG. PTEN gene mutations in colorectal cancers displaying microsatellite instability. Cancer Lett (2001) 174:189-94. doi:10.1016/S0304-3835(01)00691-7
25. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 161:439-47. doi:10.1016/S0002-9440(10)64200-9
26. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 64:3014-21. doi:10.1158/0008-5472.CAN-2401-2
27. Danielsen SA, Lind GE, Bjørnslett M, Meling GI, Rognum TO, Heim S, et al. Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation-status. Hum Mutat (2008) 29:E252-62. doi:10.1002/humu.20860
28. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 65:2554-9. doi:10.1158/0008-5472-CAN-04-3913
29. Frattini M, Signoroni S, Pilotti S, Bertario L, Benvenuti S, Zanon C, et al. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 65:11227. doi:10.1158/0008-5472.CAN-05-2780
30. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 65:10669-73. doi:10.1158/0008-5472.CAN-05-2620
31. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol (2013) 85:45-81. doi:10.1016/j.critrevonc.2012.05.001
32. Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D, et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res (2001) 7:4049-53.
33. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene (2004) 23:617-28. doi:10.1038/sj.onc.1207059
34. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol (2008) 8:56. doi:10.1186/1471-230X-8-56
35. Lin MS, Huang JX, Chen WC, Zhang BF, Fang J, Zhou Q, et al. Expression of PPAR? and PTEN in human colorectal cancer: an immunohistochemical study using tissue microarray methodology. Oncol Lett (2011) 2:1219-24.
36. Li XH, Zheng HC, Takahashi H, Masuda S, Yang XH, Takano Y. PTEN expression and mutation in colorectal carcinomas. Oncol Rep (2009) 22:757-64.
37. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology (2010) 56:229-39. doi:10.1111/j.1365-2559.2009.03468.x
38. Jin C, Wang A, Chen J, Liu X, Wang G. Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer. Exp Ther Med (2012) 4:633-9.
39. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, et al. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med (2013) 2:496-506. doi:10.1002/cam4.97
40. Bohn BA, Mina S, Krohn A, Simon R, Kluth M, Harasimowicz S, et al. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. Hum Pathol (2013) 44:1524-33. doi:10.1016/j.humpath.2012.12.006
41. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Öberg Å, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 108:2153-63. doi:10.1038/bjc.2013.212
42. Price TJ, Hardingham JE, Lee CK, Townsend AR, Wrin JW, Wilson K, et al. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Med (2013) 2:277-85. doi:10.1002/cam4.75
43. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 12:395-402. doi:10.1016/j.ccr.2007.08.030
44. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer (2007) 97:1139-45. doi:10.1038/sj.bjc.6604009
45. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 27:5497-510. doi:10.1038/onc.2008.245
46. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 69:1851-7. doi:10.1158/0008-5472.CAN-08-2466
47. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2009) 20:84-90. doi:10.1093/annonc/mdn541
48. Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer (2008) 8:234. doi:10.1186/1471-2407-8-234
49. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 27:2622-9. doi:10.1200/JCO.2008.20.2796
50. Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer (2010) 102:162-4. doi:10.1038/sj.bjc.6605471
51. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 46:1997-2009. doi:10.1016/j.ejca.2010.03.036
52. Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med (2012) 10:87. doi:10.1186/1479-5876-10-87
53. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 27:5924-30. doi:10.1200/JCO.2008.21.6796
54. Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer (2009) 100:1087-94. doi:10.1038/sj.bjc.6604848
55. Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist (2011) 16:1239-49. doi:10.1634/theoncologist.2011-0024
56. Cejas P, López-Gómez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro Carpeño J, et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Curr Cancer Drug Targets (2012) 12:124-31. doi:10.2174/156800912799095162
57. Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol (2011) 19:173-83. doi:10.1097/PAI.0b013e3181f1da13
58. Shen WH, Balajee AS, Wang J, Wu H, Eng C, PandolfiPP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 128:157-70. doi:10.1016/j.cell.2006.11.042
59. Wrighton KH. Tumour suppressors: role of nuclear PTEN revealed. Nat Rev Cancer (2011) 11:154. doi:10.1038/nrc3028
60. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res (2005) 65:8096-100. doi:10.1158/0008-5472.CAN-05-1888
61. Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, et al. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol (2012) 65:218-23. doi:10.1136/jclinpath-2011-200353